Last reviewed · How we verify
Azienda Ospedaliero-Universitaria di Parma — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
1 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Metformin-Sitagliptin-Empaglifozin-Pioglitazone | Metformin-Sitagliptin-Empaglifozin-Pioglitazone | phase 3 | Oral antidiabetic combination (metformin + DPP-4 inhibitor + SGLT2 inhibitor + thiazolidinedione) | Multiple: AMPK/mitochondrial (metformin), DPP-4 (sitagliptin), SGLT2 (empaglifozin), PPAR-γ (pioglitazone) | Diabetes |
Therapeutic area mix
- Diabetes · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for Azienda Ospedaliero-Universitaria di Parma:
- Azienda Ospedaliero-Universitaria di Parma pipeline updates — RSS
- Azienda Ospedaliero-Universitaria di Parma pipeline updates — Atom
- Azienda Ospedaliero-Universitaria di Parma pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Azienda Ospedaliero-Universitaria di Parma — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/azienda-ospedaliero-universitaria-di-parma. Accessed 2026-05-17.